Navigation Links
Cephalon Reports Another Strong Quarter
Date:10/28/2008

Record Sales of $490 Million, Up 14 Percent over Third Quarter 2007

Company Raises Full Year 2008 Sales and Earnings Guidance Introduces 2009 Adjusted Net Income Guidance, Up 27 Percent over 2008

FRAZER, Pa., Oct. 28 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today reported third quarter 2008 sales of $489.7 million, compared to sales of $428.7 million for the third quarter of 2007, and at the high end of the company's guidance of $480 - $490 million. Net income for the quarter was $112.0 million and basic income per common share was $1.64. Excluding amortization expense and certain other items, adjusted net income was $92.9 million and basic adjusted income per common share for the quarter was $1.36, compared to $1.08 for the same period in 2007, exceeding the company's guidance of $1.25 to $1.35.

Central nervous system (CNS) franchise sales were $273.7 million during the quarter, a 19 percent increase compared to the same period last year. The Pain franchise sales were $117.2 million compared to $121.8 million in the third quarter of 2007. AMRIX(R) (cyclobenzaprine hydrochloride extended- release capsules) sales increased 20 percent over the second quarter 2008. Oncology franchise sales were $52.4 million, an increase of 131 percent versus 2007. Sales of TREANDA(R) (bendamustine hydrochloride) for Injection were $24.6 million for the quarter, an increase of 71 percent over the second quarter of 2008.

"More and more patients are benefiting from the novel therapies that we offer. This has resulted in record sales, and adjusted earnings that exceeded the high end of our guidance. These solid results, and our confidence in our current product portfolio, enabled us to raise our guidance for the remainder of this year and issue adjusted net income guidance for 2009 that exceeds today's First Call consensus," said Frank Baldino, Jr., Ph.D., Chairman and CEO. "Despite troubled economic conditions around the world, our
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... and BETHESDA, Md. , ... joining together with two institutes from the National Institutes ... tools for bringing safer, more effective treatments to patients ... National Center for Advancing Translational Sciences (NCATS) and the ...
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation (OTCQX: ... and commercializing innovative therapies addressing major unmet medical ... received the Notice of Allowance from the United ... self-delivering RNAi compounds (sd-rxRNA®), for the treatment of ...
(Date:1/14/2014)... UK (PRWEB) January 13, 2014 Bob ... with more than 20 years in the industry, has ... photonics . Hainsey will serve as the society’s Science ... Dr. Hainsey join SPIE as our Technology Strategist, further ...
(Date:1/14/2014)... Independent publisher Bitingduck Press, with offices in ... big ideas for 2014 in production and sales of ... produce high-quality, low-cost, DRM-free ebooks and to use the ... The first major development will be bookstore sales in ...
Breaking Biology Technology:Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... MONICA, Calif., Oct. 9 Aida,Pharmaceuticals, Inc. ... China,s,leading pharmaceutical companies, today announced that the ... sale of Etimicin,sulfate throughout China. Aida expects ... to increase noticeably as sales efforts are,pursued ...
... Angiotech Pharmaceuticals,Inc. (NASDAQ: ANPI , TSX: ... company, today announced that it intends to ... Food and Drug Administration,(FDA) for its innovative, ... "After reviewing the data from our recently ...
... Pharmaceutical and biotech,companies reach much greater and sustained ... and marketing, balancing therapeutic,innovation with commercial focus in ... companies to break down the walls that have ... strengths of both,talented medical researchers and skillful marketers. ...
Cached Biology Technology:Sales of Etimicin Sulfate to Expand Nationwide as Government Restriction is Lifted 2Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial 2Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial 3Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial 4Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial 5Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial 6Pharmaceutical Product Launch: Commercially Focused R&D Increases Drug's Market Potential 2
(Date:4/21/2014)... which is commonly used as a farm soil fertilizer, ... genes from the cows, gut bacteria. The findings, reported ... the American Society for Microbiology, hints that cow manure ... resistance genes that transfer to bacteria in the soils ... resistance (AR) genes have already been identified, but the ...
(Date:4/21/2014)... Dallas have received a federal grant to investigate ... of many everyday products might affect human health. ... and Dr. Rockford Draper, professor of molecular and ... from the National Institute of Environmental Health Sciences, ... track how multi-walled carbon nanotubes interact with human ...
(Date:4/21/2014)... Professor Lawrence Krauss was honored at the Academia ... to public understanding of science and for his ... The Academia Film Olomouc award for Outstanding Communication ... on April 19, in Olomouc, Czech Republic. , ... of science documentary films, and the largest such ...
Breaking Biology News(10 mins):Cow manure harbors diverse new antibiotic resistance genes 2Cow manure harbors diverse new antibiotic resistance genes 3Grant to fund research on possible cell contaminants 2Grant to fund research on possible cell contaminants 3Lawrence Krauss is honored at international festival of science documentary films 2Lawrence Krauss is honored at international festival of science documentary films 3
... (Edmonton) Two University of Alberta researchers have published a step ... harmful chemicals on commercial crops by developing plants that produce ... biologist Allen Good says the energy required to produce nitrogen ... a $100 billion a year. Good says that while they ...
... adelgid, has been marching north along the Appalachians, killing almost ... forests in Georgia, Tennessee, and Virginia. The pest recently arrived ... only extreme cold stops the adelgid. But now a ... "fungal microfactory" technology that promises to give forest managers and ...
... joint meeting of the International Ethological Conference (IEC) and ... more than 1,100 researchers from around the world for ... Included among the speakers will be one of ... head of the Department of Ethology at the Etvs ...
Cached Biology News:Forest fungus factory 2Behavior 2011 to draw global contingent of more than 1,100 animal researchers to IU next week 2